Columbus, OH Clinical Trials Report — June 2026

For residents of Columbus, OH, considering participation in clinical research, June 2026 presents a window of opportunity, particularly for trials nearing their enrollment deadlines. A total of 66 clinical trials in the city are slated to conclude within the next 90 days, making prompt action essential for interested individuals.

This urgency extends to healthy volunteers, as 6 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Stroke (2 trials)
• Diabetes mellitus, type 2 (2 trials)
• Suicidal ideation (2 trials)
• Type 2 diabetes (2 trials)
• Adult congenital heart disease (1 trial)
• Allogeneic hematopoietic stem cell transplantation recipient (1 trial)
• Acute myeloid leukemia in remission (1 trial)
• Aortic insufficiency (1 trial)
• Adequate vitamin c status (1 trial)
• Aortic regurgitation (1 trial)

New Research Opportunities Emerge

This month, Columbus saw the opening of 19 new clinical trials, a decrease from the 24 trials that launched in May 2026. Despite this slight dip, the city remains a vibrant hub for medical research, with a total of 1,264 actively recruiting clinical trials across 362 research facilities.

June brings several high-profile new trials to Columbus, OH, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is initiating a notable Phase 3 study, NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This pivotal, multicenter, global, randomized, placebo-controlled, double-blind study aims for 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron once daily compared with placebo for weight management.
• Also from Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." This randomized, double-blind, placebo-controlled Phase 3 study seeks 1,100 participants to evaluate the long-term efficacy, safety, and tolerability of aleniglipron in individuals living with overweight or obesity and Type 2 Diabetes Mellitus.
• Kallyope Inc. is sponsoring a Phase 3 study, NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This double-blind, randomized, multicenter trial aims for 1,800 participants to evaluate the efficacy, safety, and tolerability of elismetrep compared with placebo in the acute treatment of migraine.
• Another study from Kallyope Inc. is NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine." This Phase 3 study aims for 1,000 participants to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.
• AstraZeneca is sponsoring NCT07662213, "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus." This Phase 3 study aims for 1,200 participants to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk.
• Vanderbilt University Medical Center is leading NCT07674758, "Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials." This study, aiming for 1,000 participants, seeks to better understand the evolution of heart dysfunction in Duchenne and Becker Muscular Dystrophy patients and carriers.

New trials this month are exploring a range of conditions, with the most frequent being obesity (2 trials), chronic weight management (2 trials), and overweight (2 trials). Drug trials account for the largest share of new studies, with 10 new drug trials opening this month.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. A total of 2 of the 19 new trials launched this month are actively seeking healthy volunteers. Across Columbus, a total of 93 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Columbus's Leading Research Facilities

Columbus is home to some of Ohio's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Ohio State University Comprehensive Cancer Center (231 trials)
• Nationwide Children's Hospital (179 trials)
• The Ohio State University (124 trials)
• Ohio State University (119 trials)
• The Ohio State University Wexner Medical Center (67 trials)
• Riverside Methodist Hospital (42 trials)
• Grant Medical Center (36 trials)
• Doctors Hospital (35 trials)
• Columbus Oncology and Hematology Associates Inc (30 trials)
• Mount Carmel East Hospital (29 trials)
• The Mark H Zangmeister Center (29 trials)
• Research Site (29 trials)

These institutions offer a broad spectrum of research, from oncology at Ohio State University Comprehensive Cancer Center and Columbus Oncology and Hematology Associates, to pediatric research at Nationwide Children's Hospital, and diverse medical fields at The Ohio State University and its Wexner Medical Center.

Broadening Your Search: Nearby Options in Ohio

While Columbus offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Ohio. Cities with active trials include Cincinnati (17 trials), Cleveland (12 trials), Dayton (6 trials), South Euclid (2 trials), West Chester (2 trials), Milford (2 trials), North Royalton (1 trial), and Wadsworth (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 19 new trials launched this month, 17 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial includes children, 1 is female-only, and 1 is male-only. Academic institutions continue to play a vital role in Columbus's research ecosystem, with Ohio State University Comprehensive Cancer Center (3 trials) and Ohio State University (3 trials) sponsoring the most new studies. Industry sponsors like Kallyope Inc. (2 trials) and Gasherbrum Bio, Inc. (2 trials) are also driving significant research efforts.

As we move through June, Columbus's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.